Molecular classification of endometrial cancer: how does it work and what does it imply for treatment and outcome?

Date: September 19th

Time: 4pm-5pm (CEST)

Speakers

Alicia León-Castillo, GYN Pathologist - Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam (NL)

Nanda Horeweg, Clinical epidemiologist Assistant Prof - Leiden University Medical Center (NL)

Bastiaan Wortman, GYN Radiation Oncologist - Catharina Hospital Eindhoven (NL)

The molecular classification of endometrial cancer has changed the way we understand and treat this common gynecological malignancy. Although the molecular classification has been integrated in the WHO classification of endometrial cancer and many guidelines, its implementation in the diagnosis and treatment is hampered. In this webinar 3 experts will summarize current knowledge about the molecular classification in endometrial cancer and translate this to current practice.

Dr. Alicia Léon is a gyneco-pathologist and has done ground-breaking work on the development of the surrogate molecular classification of endometrial cancer and the diagnostic algorithm for endometrial cancers with multiple classifying features. She will explain the different elements of the molecular classification: POLE mutations, mismatch-repair deficiency and p53 aberrations, and place them in the context of the traditional pathological risk factors. She will discuss common issues in the diagnostic phase and give an overview of the different methods that can be used to perform the molecular analysis.

Dr. Nanda Horeweg is a clinical epidemiologist in radiation oncology, and has a research line on the determinants of the efficacy and toxicity of cancer treatments. Through clinical trials, such as the PORTEC trials and RAINBO program, and translational research, she aims to identify and validate prognostic and predictive biomarkers to refine prognosis and personalize treatment. She will give an overview of studies on the prognostic and predictive value of the molecular markers in endometrial cancer and share insights on the integration of the molecular classification with established clinical and pathological risk factors.

Dr. Bastiaan Wortman has obtained a PhD for his work on the (molecular) analysis of the PORTEC clinical trials, and works as a radiation-oncologist specialized in the treatment of gynecological cancers. His academic background and clinical experience in a large peripheral hospital places him in the unique position to put research findings into perspective, and translate it into clinical practical practice. He will present clinical cases wherein the information of the molecular classification may or may not be of value, and discuss different therapeutic approaches in an interactive manner.

Summarizing, in this this webinar, you will get an overview of the current knowledge on the molecular classification of endometrial cancer, its implications for practice, and have the opportunity to interact with three experts who are looking forward to see you.